Adrenocorticotropin

The Pituitary

Volumn , Issue , 2011, Pages 47-81

  Wang, Oulu ^a   Majzoub, Joseph A ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855192195     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-380926-1.10003-3     Document Type: Chapter

References (193)

1. Kelberman D., Rizzoti K., Lovell-Badge R., Robinson I.C., Dattani M.T. Genetic regulation of pituitary gland development in human and mouse. Endocr Rev 2009, 30(7):790-829.
2. Blumenfeld Z., Jaffe R.B. Hypophysiotropic and neuromodulatory regulation of adrenocorticotropin in the human fetal pituitary gland. J Clin Invest 1986, 78(1):288-294.
3. Doniach I. Histopathology of the pituitary. Clin Endocrinol Metab 1985, 14(4):765-789.
4. Puy L.A., Ciocca D.R. Human pharyngeal and sellar pituitary glands: Differences and similarities revealed by an immunocytochemical study. J Endocrinol 1986, 108(2):231-238.
5. Hermesz E., Mackem S., Mahon K.A. Rpx: A novel anterior-restricted homeobox gene progressively activated in the prechordal plate, anterior neural plate and Rathke's pouch of the mouse embryo. Development 1996, 122:41-52.
6. Dattani M.T., Martinez-Barbera J.P., Thomas P.Q., Brickman J.M., Gupta R., Martensson I.L., et al. Mutations in the homeobox gene HESX1/Hesx1 associated with septo-optic dysplasia in human and mouse. Nat Genet 1998, 19:125-133.
7. Sheng H.Z., Zhadanov A.B., Mosinger B.J., Fujii T., Bertuzzi S., Grinberg A., et al. Specification of pituitary cell lineages by the LIM homeobox gene Lhx3. Science 1996, 272:1004-1007.
8. Szeto D.P., Ryan A.K., O'Connell S.M., Rosenfeld M.G. P-OTX: A PIT-1-interacting homeodomain factor expressed during anterior pituitary gland development. Proc Nat Acad Sci USA 1996, 93:7706-7710.
9. Lanctot C., Gauthier Y., Drouin J. Pituitary homeobox 1 (Ptx1) is differentially expressed during pituitary development. Endocrinology 1999, 140:1416-1422.
10. Tremblay J.J., Lanctot C., Drouin J. The pan-pituitary activator of transcription, Ptx1 (pituitary homeobox 1), acts in synergy with SF-1 and Pit1 and is an upstream regulator of the Lim-homeodomain gene Lim3/Lhx3. Mol Endocrinol 1998, 12:428-441.
11. Semina E.V., Reiter R., Leysens N.J., Alward W.L., Small K.W., Datson N.A., et al. Cloning and characterization of a novel bicoid-related homeobox transcription factor gene, RIEG, involved in Rieger syndrome. Nat Genet 1996, 14:392-399.
12. Li S., Crenshaw E.B., Rawson E.J., Simmons D.M., Swanson L.W., Rosenfeld M.G. Dwarf locus mutants lacking three pituitary cell types result from mutations in the POU-domain gene pit-1. Nature 1990, 347:528-533.
13. Lee J.E., Hollenberg S.M., Snider L., Turner D.L., Lipnick N., Weintraub H. Conversion of Xenopus ectoderm into neurons by NeuroD, a basic helix-loop-helix protein. Science 1995, 268:836-844.
14. Naya F.J., Stellrecht C.M., Tsai M.J. Tissue-specific regulation of the insulin gene by a novel basic helix-loop-helix transcription factor. Genes Dev 1995, 9:1009-1019.
15. Drouin J., Bilodeau S., Vallette S. Of old and new diseases: Genetics of pituitary ACTH excess (Cushing) and deficiency. Clin Genet 2007, 72(3):175-182.
16. Karpac J., Ostwald D., Li G.Y., Bui S., Hunnewell P., Brennan M.B., et al. Proopiomelanocortin heterozygous and homozygous null mutant mice develop pituitary adenomas. Cell Mol Biol (Noisy-le-grand) 2006, 52(2):47-52.
17. Dunn K.J., Williams B.O., Li Y., Pavan W.J. Neural crest-directed gene transfer demonstrates Wnt1 role in melanocyte expansion and differentiation during mouse development. Proc Nat Acad Sci USA 2000, 97(18):10050-10055.
18. Liu N.A., Huang H., Yang Z., Herzog W., Hammerschmidt M., Lin S., et al. Pituitary corticotroph ontogeny and regulation in transgenic zebrafish. Mol Endocrinol 2003, 17(5):959-966.
19. Kimura S., Hara Y., Pineau T., Fernandez-Salguero P., Fox C.H., Ward J.M., et al. The T/ebp null mouse: Thyroid-specific enhancer-binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary. Genes Dev 1996, 10:60-69.
20. Muglia L., Jacobson L., Dikkes P., Majzoub J.A. Corticotropin-releasing hormone deficiency reveals major fetal but not adult glucocorticoid need. Nature 1995, 373:427-432.
21. Schonemann M.D., Ryan A.K., McEvilly R.J., O'Connell S.M., Arias C.A., Kalla K.A., et al. Development and survival of the endocrine hypothalamus and posterior pituitary gland requires the neuronal POU domain factor Brn-2. Genes Dev 1995, 9:3122-3135.
22. Denef C. Paracrinicity: The story of 30 years of cellular pituitary crosstalk. J Neuroendocrinol 2008, 20(1):1-70.
23. Kitahara A., Takano E., Ohtsuki H., Kirihata Y., Yamagata Y., Kannagi R., et al. Reversed distribution of calpains and calpastatin in human pituitary gland and selective localization of calpastatin in adrenocorticotropin-producing cells as demonstrated by immunohistochemistry. J Clin Endocrinol Metab 1986, 63(2):343-348.
24. Uei Y. Immunohistological study of Crooke's cells. Pathol Res Pract 1988, 183(5):636-637.
25. Desy L., Pelletier G. Immunohistochemical localization of alpha-melanocyte stimulating hormone (alpha-MSH) in the human hypothalamus. Brain Res 1978, 154(2):377-381.
26. Emson P.C., Corder R., Ratter S.J., Tomlin S., Lowry P.J., Ress L.H., et al. Regional distribution of pro-opiomelanocortin-derived peptides in the human brain. Neuroendocrinology 1984, 38(1):45-50.
27. Broberger C., Johansen J., Johansson C., Schalling M., Hokfelt T. The neuropeptide Y/agouti gene-related protein (AGRP) brain circuitry in normal, anorectic, and monosodium glutamate-treated mice. Proc Nat Acad Sci USA 1998, 95:15043-15048.
28. Cheung C.C., Clifton D.K., Steiner R.A. Proopiomelanocortin neurons are direct targets for leptin in the hypothalamus. Endocrinology 1997, 138:4489-4492.
29. DeBold C.R., Menefee J.K., Nicholson W.E., Orth D.N. Proopiomelanocortin gene is expressed in many normal human tissues and in tumors not associated with ectopic adrenocorticotropin syndrome. Mol Endocrinol 1988, 2(9):862-870.
30. Lacaze-Masmonteil T., de Keyzer Y., Luton J.P., Kahn A., Bertagna X. Characterization of proopiomelanocortin transcripts in human nonpituitary tissues. Proc Nat Acad Sci USA 1987, 84:7261-7265.
31. Bicknell A.B. The tissue-specific processing of pro-opiomelanocortin. J Neuroendocrinol 2008, 20(6):692-699.
32. Jenks B.G. Regulation of proopiomelanocortin gene expression: An overview of the signaling cascades, transcription factors, and responsive elements involved. Ann NY Acad Sci 2009, 1163:17-30.
33. Fremeau R.T.J., Lundblad J.R., Pritchett D.B., Wilcox J.N., Roberts J.L. Regulation of pro-opiomelanocortin gene transcription in individual cell nuclei. Science 1986, 234:1265-1269.
34. Aguilera G., Nikodemova M., Wynn P.C., Catt K.J. Corticotropin releasing hormone receptors: Two decades later. Peptides 2004, 25(3):319-329.
35. Bousquet C., Susini C., Melmed S. Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor. J Clin Invest 1999, 104(9):1277-1285.
36. Yano H., Readhead C., Nakashima M., Ren S.G., Melmed S. Pituitary-directed leukemia inhibitory factor transgene causes Cushing's syndrome: Neuro-immune-endocrine modulation of pituitary development. Mol Endocrinol 1998, 12(11):1708-1720.
37. Iwasaki Y., Nishiyama M., Taguchi T., Kambayashi M., Asai M., Yoshida M., et al. Activation of AMP-activated protein kinase stimulates proopiomelanocortin gene transcription in AtT20 corticotroph cells. Am J Physiol Endocrinol Metab 2007, 292(6):E1899-E1905.
38. Yang G., Lim C.Y., Li C., Xiao X., Radda G.K., Cao X., et al. FoxO1 inhibits leptin regulation of pro-opiomelanocortin promoter activity by blocking STAT3 interaction with specificity protein 1. J Biol Chem 2009, 284(6):3719-3727.
39. Kageyama K., Suda T. Regulatory mechanisms underlying corticotropin-releasing factor gene expression in the hypothalamus. Endocr J 2009, 56(3):335-344.
40. Robinson B.G., Mealy K., Wilmore D.W., Majzoub J.A. The effect of insulin-induced hypoglycemia on gene expression in the hypothalamic-pituitary-adrenal axis of the rat. Endocrinology 1992, 130(2):920-925.
41. Korner J., Chun J., Harter D., Axel R. Isolation and functional expression of a mammalian prohormone processing enzyme, murine prohormone convertase 1. Proc Nat Acad Sci USA 1991, 88(15):6834-6838.
42. Jackson R.S., Creemers J.W., Ohagi S., Raffin-Sanson M.L., Sanders L., Montague C.T., et al. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene [see comments]. Nat Genet 1997, 16:303-306.
43. Naggert J.K., Fricker L.D., Varlamov O., Nishina P.M., Rouille Y., Steiner D.F., et al. Hyperproinsulinaemia in obese fat/fat mice associated with a carboxypeptidase E mutation which reduces enzyme activity. Nat Genet 1995, 10:135-142.
44. Malide D., Seidah N.G., Chretien M., Bendayan M. Electron microscopic immunocytochemical evidence for the involvement of the convertases PC1 and PC2 in the processing of proinsulin in pancreatic beta-cells. J Histochem Cytochem 1995, 43:11-19.
45. Braks J.A., Martens G.J. 7B2 is a neuroendocrine chaperone that transiently interacts with prohormone convertase PC2 in the secretory pathway. Cell 1994, 78:263-273.
46. Westphal C.H., Muller L., Zhou A., Zhu X., Bonner-Weir S., Schambelan M., et al. The neuroendocrine protein 7B2 is required for peptide hormone processing in vivo and provides a novel mechanism for pituitary Cushing's disease. Cell 1999, 96:689-700.
47. Furuta M., Yano H., Zhou A., Rouille Y., Holst J.J., Carroll R., et al. Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2. Proc Nat Acad Sci USA 1997, 94:6646-6651.
48. Fricker L.D., McKinzie A.A., Sun J., Curran E., Qian Y., Yan L., et al. Identification and characterization of proSAAS, a granin-like neuroendocrine peptide precursor that inhibits prohormone processing. J Neurosci 2000, 20:639-648.
49. Saiardi A., Borrelli E. Absence of dopaminergic control on melanotrophs leads to Cushing's-like syndrome in mice. Mol Endocrinol 1998, 12:1133-1139.
50. Yalow R.S. Radioimmunoassay: A probe for the fine structure of biologic systems. Science 1978, 200(4347):1236-1245.
51. Lindsay J.R., Shanmugam V.K., Oldfield E.H., Remaley A.T., Nieman L.K. A comparison of immunometric and radioimmunoassay measurement of ACTH for the differential diagnosis of Cushing's syndrome. J Endocrinol Invest 2006, 29(11):983-988.
52. Dobson S., White A., Hoadley M., Lovgren T., Ratcliffe J. Measurement of corticotropin in unextracted plasma: Comparison of a time-resolved immunofluorometric assay and an immunoradiometric assay, with use of the same monoclonal antibodies. Clin Chem 1987, 33(10):1747-1751.
53. Verschraegen I., Anckaert E., Schiettecatte J., Mees M., Garrido A., Hermsen D., et al. Multicenter evaluation of a rapid electrochemiluminescent adrenocorticotropic hormone (ACTH) immunoassay. Clin Chim Acta 2007, 380(1-2):75-80.
54. Thomas A., Kohler M., Schanzer W., Kamber M., Delahaut P., Thevis M. Determination of Synacthen in urine for sports drug testing by means of nano-ultra-performance liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2009, 23(17):2669-2674.
55. Aguilera G., Rabadan-Diehl C., Nikodemova M. Regulation of pituitary corticotropin releasing hormone receptors. Peptides 2001, 22(5):769-774.
56. Jessop D.S. Review: Central non-glucocorticoid inhibitors of the hypothalamo-pituitary-adrenal axis. J Endocrinol 1999, 160(2):169-180.
57. Gibbs D.M., Stewart R.D., Vale W., Rivier J., Yen S.S. Synthetic corticotropin-releasing factor stimulates secretion of immunoreactive beta-endorphin/beta-lipotropin and ACTH by human fetal pituitaries in vitro. Life Sci 1983, 32(5):547-550.
58. DeBold C.R., Sheldon W.R., DeCherney G.S., Jackson R.V., Nicholson W.E., Island D.P., et al. Effect of subcutaneous and intranasal administration of ovine corticotropin-releasing hormone in man: Comparison with intravenous administration. J Clin Endocrinol Metab 1985, 60(5):836-840.
59. Smith R., Mesiano S., Chan E.C., Brown S., Jaffe R.B. Corticotropin-releasing hormone directly and preferentially stimulates dehydroepiandrosterone sulfate secretion by human fetal adrenal cortical cells. J Clin Endocrinol Metab 1998, 83(8):2916-2920.
60. DeBold C.R., DeCherney G.S., Jackson R.V., Sheldon W.R., Alexander A.N., Island D.P., et al. Effect of synthetic ovine corticotropin-releasing factor: Prolonged duration of action and biphasic response of plasma adrenocorticotropin and cortisol. J Clin Endocrinol Metab 1983, 57(2):294-298.
61. Michie H.R., Majzoub J.A., O'Dwyer S.T., Revhaug A., Wilmore D.W. Both cyclooxygenase-dependent and cyclooxygenase-independent pathways mediate the neuroendocrine response in humans. Surgery 1990, 108(2):254-259. discussion 9-61.
62. Gaillard R.C., Riondel A.M., Ling N., Muller A.F. Corticotropin releasing factor activity of CRF 41 in normal man is potentiated by angiotensin II and vasopressin but not by desmopressin. Life Sci 1988, 43(23):1935-1944.
63. Watanabe T., Oki Y., Orth D.N. Kinetic actions and interactions of arginine vasopressin, angiotensin-II, and oxytocin on adrenocorticotropin secretion by rat anterior pituitary cells in the microperifusion system. Endocrinology 1989, 125(4):1921-1931.
64. Schoenenberg P., Gaillard R.C., Kehrer P., Muller A.F. cAMP-dependent ACTH secretagogues facilitate corticotropin releasing activity of angiotensin II on rat anterior pituitary cells in vitro. Acta Endocrinol (Copenh) 1987, 114(1):118-123.
65. Weninger S.C., Dunn A.J., Muglia L.J., Dikkes P., Miczek K.A., Swiergiel A.H., et al. Stress-induced behaviors require the corticotropin-releasing hormone (CRH) receptor, but not CRH. Proc Nat Acad Sci USA 1999, 96(14):8283-8288.
66. Zoumakis E., Rice K.C., Gold P.W., Chrousos G.P. Potential uses of corticotropin-releasing hormone antagonists. Ann NY Acad Sci 2006, 1083:239-251.
67. Rivier C., Vale W. Effects of corticotropin-releasing factor, neurohypophyseal peptides, and catecholamines on pituitary function. Fed Proc 1985, 44(1 Pt 2):189-195.
68. Sharp B.M., Matta S.G., Peterson P.K., Newton R., Chao C., McAllen K. Tumor necrosis factor-alpha is a potent ACTH secretagogue: Comparison to interleukin-1 beta. Endocrinology 1989, 124(6):3131-3133.
69. Michie H.R., Manogue K.R., Spriggs D.R., Revhaug A., O'Dwyer S., Dinarello C.A., et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988, 318(23):1481-1486.
70. Naitoh Y., Fukata J., Tominaga T., Nakai Y., Tamai S., Mori K., et al. Interleukin-6 stimulates the secretion of adrenocorticotropic hormone in conscious, freely-moving rats. Biochem Biophys Res Commun 1988, 155(3):1459-1463.
71. Navarra P., Tsagarakis S., Faria M.S., Rees L.H., Besser G.M., Grossman A.B. Interleukins-1 and -6 stimulate the release of corticotropin-releasing hormone-41 from rat hypothalamus in vitro via the eicosanoid cyclooxygenase pathway. Endocrinology 1991, 128(1):37-44.
72. Koenig J.I. Pituitary gland: Neuropeptides, neurotransmitters and growth factors. Toxicol Pathol 1989, 17(2):256-265.
73. Volavka J., Cho D., Mallya A., Bauman J. Naloxone increases ACTH and cortisol levels in man. N Engl J Med 1979, 300(18):1056-1057.
74. Wakabayashi I., Demura R., Miki N., Ohmura E., Miyoshi H., Shizume K. Failure of naloxone to influence plasma growth hormone, prolactin, and cortisol secretions induced by insulin hypoglycemia. J Clin Endocrinol Metab 1980, 50(3):597-599.
75. Rittmaster R.S., Cutler G.B., Sobel D.O., Goldstein D.S., Koppelman M.C., Loriaux D.L., et al. Morphine inhibits the pituitary-adrenal response to ovine corticotropin-releasing hormone in normal subjects. J Clin Endocrinol Metab 1985, 60(5):891-895.
76. Allolio B., Deuss U., Kaulen D., Leonhardt U., Kallabis D., Hamel E., et al. FK 33-824, a met-enkephalin analog, blocks corticotropin-releasing hormone-induced adrenocorticotropin secretion in normal subjects but not in patients with Cushing's disease. J Clin Endocrinol Metab 1986, 63(6):1427-1431.
77. Schmidt A., Audigier S., Barberis C., Jard S., Manning M., Kolodziejczyk A.S., et al. A radioiodinated linear vasopressin antagonist: A ligand with high affinity and specificity for V1a receptors. FEBS Lett 1991, 282(1):77-81.
78. Spinedi E., Negro-Vilar A. Arginine vasopressin and adrenocorticotropin release: Correlation between binding characteristics and biological activity in anterior pituitary dispersed cells. Endocrinology 1984, 114(6):2247-2251.
79. Aguilera G., Volpi S., Rabadan-Diehl C. Transcriptional and post-transcriptional mechanisms regulating the rat pituitary vasopressin V1b receptor gene. J Mol Endocrinol 2003, 30(2):99-108.
80. Watanabe T., Orth D.N. Detailed kinetic analysis of adrenocorticotropin secretion by dispersed rat anterior pituitary cells in a microperifusion system: Effects of ovine corticotropin-releasing factor and arginine vasopressin. Endocrinology 1987, 121(3):1133-1145.
81. Page S.R., Ang V.T., Jackson R., Nussey S.S. The effect of oxytocin on the plasma glucagon response to insulin-induced hypoglycaemia in man. Diabetes Metab 1990, 16(3):248-251.
82. Mishunina T.M., Kononenko V.Y. Specific GABA binding in the adrenals and blood corticosteroid levels in stress in intact rats and rats with changes in the functional activity of the hypothalamo-pituitary-adrenal system. Neurosci Behav Physiol 2002, 32(2):109-112.
83. Mountjoy K.G., Robbins L.S., Mortrud M.T., Cone R.D. The cloning of a family of genes that encode the melanocortin receptors. Science 1992, 257:1248-1251.
84. Clark A.J., Chan L.F., Chung T.T., Metherell L.A. The genetics of familial glucocorticoid deficiency. Best Pract Res Clin Endocrinol Metab 2009 Apr, 23(2):159-165.
85. Schioth H.B., Muceniece R., Wikberg J.E. Characterisation of the melanocortin 4 receptor by radioligand binding. Pharmacol Toxicol 1996, 79:161-165.
86. Strand F.L., Saint-Come C., Lee T.S., Lee S.J., Kume J., Zuccarelli L.A. ACTH/MSH(4-10) analog BIM 22015 aids regeneration via neurotrophic and myotrophic attributes. Peptides 1993, 14:287-296.
87. Cone R.D., Mountjoy K.G., Robbins L.S., Nadeau J.H., Johnson K.R., Roselli-Rehfuss L., et al. Cloning and functional characterization of a family of receptors for the melanotropic peptides. Ann NY Acad Sci 1993, 680:342-363.
88. Suzuki I., Cone R.D., Im S., Nordlund J., Abdel-Malek Z.A. Binding of melanotropic hormones to the melanocortin receptor MC1R on human melanocytes stimulates proliferation and melanogenesis. Endocrinology 1996, 137:1627-1633.
89. Chakraborty A.K., Funasaka Y., Pawelek J.M., Nagahama M., Ito A., Ichihashi M. Enhanced expression of melanocortin-1 receptor (MC1-R) in normal human keratinocytes during differentiation: Evidence for increased expression of POMC peptides near suprabasal layer of epidermis. J Invest Dermatol 1999, 112:853-860.
90. Robbins L.S., Nadeau J.H., Johnson K.R., Kelly M.A., Roselli-Rehfuss L., Baack E., et al. Pigmentation phenotypes of variant extension locus alleles result from point mutations that alter MSH receptor function. Cell 1993, 72:827-834.
91. Valverde P., Healy E., Jackson I., Rees J.L., Thody A.J. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans [see comments]. Nat Genet 1995, 11:328-330.
92. Healy E., Flannagan N., Ray A., Todd C., Jackson I.J., Matthews J.N., et al. Melanocortin-1-receptor gene and sun sensitivity in individuals without red hair [letter]. Lancet 2000, 355:1072-1073.
93. Luger T.A., Scholzen T., Brzoska T., Becher E., Slominski A., Paus R. Cutaneous immunomodulation and coordination of skin stress responses by alpha-melanocyte-stimulating hormone. Ann NY Acad Sci 1998, 840:381-394.
94. Star R.A., Rajora N., Huang J., Stock R.C., Catania A., Lipton J.M. Evidence of autocrine modulation of macrophage nitric oxide synthase by alpha-melanocyte-stimulating hormone. Proc Nat Acad Sci USA 1995, 92:8016-8020.
95. Catania A., Rajora N., Capsoni F., Minonzio F., Star R.A., Lipton J.M. The neuropeptide alpha-MSH has specific receptors on neutrophils and reduces chemotaxis in vitro. Peptides 1996, 17:675-679.
96. Hartmeyer M., Scholzen T., Becher E., Bhardwaj R.S., Schwarz T., Luger T.A. Human dermal microvascular endothelial cells express the melanocortin receptor type 1 and produce increased levels of IL-8 upon stimulation with alpha-melanocyte-stimulating hormone. J Immunol 1997, 159:1930-1937.
97. Elias L.L., Huebner A., Pullinger G.D., Mirtella A., Clark A.J. Functional characterization of naturally occurring mutations of the human adrenocorticotropin receptor: Poor correlation of phenotype and genotype. J Clin Endocrinol Metab 1999, 84:2766-2770.
98. Metherell L.A., Chapple J.P., Cooray S., David A., Becker C., Ruschendorf F., et al. Mutations in MRAP, encoding a new interacting partner of the ACTH receptor, cause familial glucocorticoid deficiency type 2. Nat Genet 2005, 37(2):166-170.
99. Cooray S.N., Chan L., Metherell L., Storr H., Clark A.J. Adrenocorticotropin resistance syndromes. Endocr Dev 2008, 13:99-116.
100. Sebag J.A., Hinkle P.M. Melanocortin-2 receptor accessory protein MRAP forms antiparallel homodimers. Proc Nat Acad Sci USA 2007, 104(51):20244-20249.
101. Sebag J.A., Hinkle P.M. Regions of melanocortin 2 (MC2) receptor accessory protein necessary for dual topology and MC2 receptor trafficking and signaling. J Biol Chem 2009, 284(1):610-618.
102. Webb T.R., Clark A.J. Minireview: The melanocortin 2 receptor accessory proteins. Mol Endocrinol 2009, 24(3):475-484.
103. Miller W.L., Strauss J.F. Molecular pathology and mechanism of action of the steroidogenic acute regulatory protein, StAR. J Steroid Biochem Mol Biol 1999, 69(1-6):131-141.
104. Estivariz F.E., Iturriza F., McLean C., Hope J., Lowry P.J. Stimulation of adrenal mitogenesis by N-terminal proopiocortin peptides. Nature 1982, 297:419-422.
105. Albright F. Osteoporosis, Annals of Internal Medicine 1947, 27:861-882.
106. Linder B.L., Esteban N.V., Yergey A.L., Winterer J.C., Loriaux D.L., Cassorla F. Cortisol production rate in childhood and adolescence. J Pediatr 1990, 117(6):892-896.
107. Boston B.A., Cone R.D. Characterization of melanocortin receptor subtype expression in murine adipose tissues and in the 3T3-L1 cell line. Endocrinology 1996, 137:2043-2050.
108. Bousquet-Melou A., Galitzky J., Lafontan M., Berlan M. Control of lipolysis in intra-abdominal fat cells of nonhuman primates: Comparison with humans. J Lipid Res 1995, 36:451-461.
109. Smith E.M., Brosnan P., Meyer W.J., Blalock J.E. An ACTH receptor on human mononuclear leukocytes. Relation to adrenal ACTH-receptor activity. N Engl J Med 1987, 317:1266-1269.
110. Slominski A., Ermak G., Hwang J., Mazurkiewicz J., Corliss D., Eastman A. The expression of proopiomelanocortin (POMC) and of corticotropin releasing hormone receptor (CRH-R) genes in mouse skin. Biochim Biophys Acta 1996, 1289:247-251.
111. Kapas S., Cammas F.M., Hinson J.P., Clark A.J. Agonist and receptor binding properties of adrenocorticotropin peptides using the cloned mouse adrenocorticotropin receptor expressed in a stably transfected HeLa cell line. Endocrinology 1996, 137:3291-3294.
112. Lindblom J., Schioth H.B., Larsson A., Wikberg J.E., Bergstrom L. Autoradiographic discrimination of melanocortin receptors indicates that the MC3 subtype dominates in the medial rat brain. Brain Res 1998, 810:161-171.
113. Getting S.J., Flower R.J., Perretti M. Agonism at melanocortin receptor type 3 on macrophages inhibits neutrophil influx. Inflamm Res 1999, 48:S140-S141.
114. Chen A.S., Marsh D.J., Trumbauer M.E., Frazier E.G., Guan X.M., Yu H., et al. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat Genet 2000, 26(1):97-102.
115. Cummings D.E., Schwartz M.W. Melanocortins and body weight: A tale of two receptors. Nat Genet 2000, 26(1):8-9.
116. Mountjoy K.G., Mortrud M.T., Low M.J., Simerly R.B., Cone R.D. Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. Mol Endocrinol 1994, 8:1298-1308.
117. Vaisse C., Clement K., Durand E., Hercberg S., Guy-Grand B., Froguel P. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity [see comments]. J Clin Invest 2000, 106:253-262.
118. Vaisse C., Clement K., Guy-Grand B., Froguel P. A frameshift mutation in human MC4R is associated with a dominant form of obesity [letter]. Nat Genet 1998, 20:113-114.
119. Farooqi I.S., Yeo G.S., Keogh J.M., Aminian S., Jebb S.A., Butler G., et al. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency [see comments]. J Clin Invest 2000, 106:271-279.
120. Cody J.D., Reveles X.T., Hale D.E., Lehman D., Coon H., Leach R.J. Haplosufficiency of the melancortin-4 receptor gene in individuals with deletions of 18q. Hum Genet 1999, 105:424-427.
121. Ho G., MacKenzie R.G. Functional characterization of mutations in melanocortin-4 receptor associated with human obesity. J Biol Chem 1999, 274:35816-35822.
122. Chambers J.C., Elliott P., Zabaneh D., Zhang W., Li Y., Froguel P., et al. Common genetic variation near MC4R is associated with waist circumference and insulin resistance. Nat Genet 2008, 40(6):716-718.
123. Balthasar N. Genetic dissection of neuronal pathways controlling energy homeostasis. Obesity (Silver Spring) 2006, 14(Suppl 5):222S-227S.
124. Cowley M.A., Pronchuk N., Fan W., Dinulescu D.M., Colmers W.F., Cone R.D. Integration of NPY, AGRP, and melanocortin signals in the hypothalamic paraventricular nucleus: evidence of a cellular basis for the adipostat. Neuron 1999, 24:155-163.
125. Kask A., Schioth H.B. Tonic inhibition of food intake during inactive phase is reversed by the injection of the melanocortin receptor antagonist into the paraventricular nucleus of the hypothalamus and central amygdala of the rat. Brain Res 2000, 887(2):460-464.
126. Dhillon H., Zigman J.M., Ye C., Lee C.E., McGovern R.A., Tang V., et al. Leptin directly activates SF1 neurons in the VMH, and this action by leptin is required for normal body-weight homeostasis. Neuron 2006, 49(2):191-203.
127. Friedman J.M. Obesity: Causes and control of excess body fat. Nature 2009, 459(7245):340-342.
128. Caro J.F., Kolaczynski J.W., Nyce M.R., Ohannesian J.P., Opentanova I., Goldman W.H., et al. Decreased cerebrospinal-fluid/serum leptin ratio in obesity: A possible mechanism for leptin resistance. Lancet 1996, 348(9021):159-161.
129. Hosoi T., Sasaki M., Miyahara T., Hashimoto C., Matsuo S., Yoshii M., et al. Endoplasmic reticulum stress induces leptin resistance. Mol Pharmacol 2008, 74(6):1610-1619.
130. Zhang X., Zhang G., Zhang H., Karin M., Bai H., Cai D. Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. Cell 2008, 135(1):61-73.
131. Ozcan U., Cao Q., Yilmaz E., Lee A.H., Iwakoshi N.N., Ozdelen E., et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004, 306(5695):457-461.
132. Ozcan L., Ergin A.S., Lu A., Chung J., Sarkar S., Nie D., et al. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab 2009, 9(1):35-51.
133. Delepine M., Nicolino M., Barrett T., Golamaully M., Lathrop G.M., Julier C. EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nat Genet 2000, 25(4):406-409.
134. Oyadomari S., Koizumi A., Takeda K., Gotoh T., Akira S., Araki E., et al. Targeted disruption of the Chop gene delays endoplasmic reticulum stress-mediated diabetes. J Clin Invest 2002, 109(4):525-532.
135. Chen W., Kelly M.A., Opitz-Araya X., Thomas R.E., Low M.J., Cone R.D. Exocrine gland dysfunction in MC5-R-deficient mice: Evidence for coordinated regulation of exocrine gland function by melanocortin peptides. Cell 1997, 91:789-798.
136. Krude H., Biebermann H., Luck W., Horn R., Brabant G., Gruters A. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 1998, 19:155-157.
137. Krude H., Biebermann H., Schnabel D., Tansek M.Z., Theunissen P., Mullis P.E., et al. Obesity due to proopiomelanocortin deficiency: Three new cases and treatment trials with thyroid hormone and ACTH4-10. J Clin Endocrinol Metab 2003, 88(10):4633-4640.
138. Flanagan N., Healy E., Ray A., Philips S., Todd C., Jackson I.J., et al. Pleiotropic effects of the melanocortin 1 receptor (MC1R) gene on human pigmentation. Hum Mol Genet 2000, 9(17):2531-2537.
139. Kikuchi T., Yabe S., Kanda T., Kobayashi I. Antipituitary antibodies as pathogenetic factors in patients with pituitary disorders. Endocr J 2000, 47(4):407-416.
140. Yaswen L., Diehl N., Brennan M.B., Hochgeschwender U. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin [see comments]. Nat Med 1999, 5:1066-1070.
141. Forbes S., Bui S., Robinson B.R., Hochgeschwender U., Brennan M.B. Integrated control of appetite and fat metabolism by the leptin-proopiomelanocortin pathway. Proc Nat Acad Sci USA 2001, 98(7):4233-4237.
142. Linhart K.B., Majzoub J.A. Pomc knockout mice have secondary hyperaldosteronism despite an absence of adrenocorticotropin. Endocrinology 2008, 149(2):681-686.
143. Silvers W.K., Russell E.S. An experimental approach to action of genes at the agouti locus in the mouse. J Exp Zool 1955, 130:199-220.
144. Cuneot L. Les races pures et leurs combinaisons chez les souris. Arch Xool Exp Gen 1905, 3:123-132.
145. Lu D., Willard D., Patel I.R., Kadwell S., Overton L., Kost T., et al. Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor. Nature 1994, 371:799-802.
146. Bultman S.J., Michaud E.J., Woychik R.P. Molecular characterization of the mouse agouti locus. Cell 1992, 71:1195-1204.
147. Ollmann M.M., Wilson B.D., Yang Y.K., Kerns J.A., Chen Y., Gantz I., et al. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein [published erratum appears in Science (1998) 281 (5383) 1615]. Science 1997, 278:135-138.
148. Yang Y.K., Thompson D.A., Dickinson C.J., Wilken J., Barsh G.S., Kent S.B., et al. Characterization of Agouti-related protein binding to melanocortin receptors. Mol Endocrinol 1999, 13:148-155.
149. Luquet S., Perez F.A., Hnasko T.S., Palmiter R.D. NPY/AgRP neurons are essential for feeding in adult mice but can be ablated in neonates. Science 2005, 310(5748):683-685.
150. Argiolas A., Melis M.R., Murgia S., Schioth H.B. ACTH- and alpha-MSH-induced grooming, stretching, yawning and penile erection in male rats: Site of action in the brain and role of melanocortin receptors [In Process Citation]. Brain Res Bull 2000, 51:425-431.
151. Wessells H., Fuciarelli K., Hansen J., Hadley M.E., Hruby V.J., Dorr R., et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: Double-blind, placebo controlled crossover study. J Urol 1998, 160:389-393.
152. Murphy M.T., Richards D.B., Lipton J.M. Antipyretic potency of centrally administered alpha-melanocyte stimulating hormone. Science 1983, 221:192-193.
153. Li S.J., Varga K., Archer P., Hruby V.J., Sharma S.D., Kesterson R.A., et al. Melanocortin antagonists define two distinct pathways of cardiovascular control by alpha- and gamma-melanocyte-stimulating hormones. J Neurosci 1996, 16:5182-5188.
154. Veldhuis J.D., Roelfsema F., Iranmanesh A., Carroll B.J., Keenan D.M., Pincus S.M. Basal, pulsatile, entropic (patterned), and spiky (staccato-like) properties of ACTH secretion: Impact of age, gender, and body mass index. J Clin Endocrinol Metab 2009, 94(10):4045-4052.
155. Veldhuis J.D., Anderson S.M., Shah N., Bray M., Vick T., Gentili A., et al. Neurophysiological regulation and target-tissue impact of the pulsatile mode of growth hormone secretion in the human. Growth Horm IGF Res 2001, 11(Suppl A):S25-S37.
156. Dallman M.F. Fast glucocorticoid actions on brain: Back to the future. Front Neuroendocrinol 2005, 26(3-4):103-108.
157. Oelkers W. Hyponatremia and inappropriate secretion of vasopressin (antidiuretic hormone) in patients with hypopituitarism. N Engl J Med 1989, 321(8):492-496.
158. Bouley R., Breton S., Sun T., McLaughlin M., Nsumu N.N., Lin H.Y., et al. Nitric oxide and atrial natriuretic factor stimulate cGMP-dependent membrane insertion of aquaporin 2 in renal epithelial cells. J Clin Invest 2000, 106(9):1115-1126.
159. Van Cauter E. Putative roles of melatonin in glucose regulation. Therapie 1998, 53(5):467-472.
160. Sasaki A., Shinkawa O., Yoshinaga K. Placental corticotropin-releasing hormone may be a stimulator of maternal pituitary adrenocorticotropic hormone secretion in humans. J Clin Invest 1989, 84(6):1997-2001.
161. Muglia L.J., Jacobson L., Weninger S.C., Luedke C.E., Bae D.S., Jeong K.H., et al. Impaired diurnal adrenal rhythmicity restored by constant infusion of corticotropin-releasing hormone in corticotropin-releasing hormone-deficient mice. J Clin Invest 1997, 99(12):2923-2929.
162. Muglia L.J., Jacobson L., Luedke C., Vogt S.K., Schaefer M.L., Dikkes P., et al. Corticotropin-releasing hormone links pituitary adrenocorticotropin gene expression and release during adrenal insufficiency. J Clin Invest 2000, 105(9):1269-1277.
163. So A.Y., Bernal T.U., Pillsbury M.L., Yamamoto K.R., Feldman B.J. Glucocorticoid regulation of the circadian clock modulates glucose homeostasis. Proc Nat Acad Sci USA 2009, 106(41):17582-17587.
164. Ellis M.J., Schmidli R.S., Donald R.A., Livesey J.H., Espiner E.A. Plasma corticotrophin-releasing factor and vasopressin responses to hypoglycaemia in normal man. Clin Endocrinol (Oxf) 1990, 32(1):93-100.
165. Deuster P.A., Chrousos G.P., Luger A., DeBolt J.E., Bernier L.L., Trostmann U.H., et al. Hormonal and metabolic responses of untrained, moderately trained, and highly trained men to three exercise intensities. Metabolism 1989, 38(2):141-148.
166. Janal M.N., Colt E.W., Clark W.C., Glusman M. Pain sensitivity, mood and plasma endocrine levels in man following long-distance running: Effects of naloxone. Pain 1984, 19(1):13-25.
167. Wang T., Hung C.C., Randall D.J. The comparative physiology of food deprivation: From feast to famine. Annu Rev Physiol 2006, 68:223-251.
168. Drazen D.L., Wortman M.D., Schwartz M.W., Clegg D.J., van Dijk G., Woods S.C., et al. Adrenalectomy alters the sensitivity of the central nervous system melanocortin system. Diabetes 2003, 52(12):2928-2934.
169. Pitts A.F., Preston M.A., Jaeckle R.S., Meller W., Kathol R.G. Simulated acute hemorrhage through lower body negative pressure as an activator of the hypothalamic-pituitary-adrenal axis. Horm Metab Res 1990, 22(8):436-443.
170. Udelsman R., Norton J.A., Jelenich S.E., Goldstein D.S., Linehan W.M., Loriaux D.L., et al. Responses of the hypothalamic-pituitary-adrenal and renin-angiotensin axes and the sympathetic system during controlled surgical and anesthetic stress. J Clin Endocrinol Metab 1987, 64(5):986-994.
171. Voigt K., Ziegler M., Grunert-Fuchs M., Bickel U., Fehm-Wolfsdorf G. Hormonal responses to exhausting physical exercise: The role of predictability and controllability of the situation. Psychoneuroendocrinology 1990, 15(3):173-184.
172. Arduini D., Rizzo G., Parlati E., Giorlandino C., Valensise H., Dell'Acqua S., et al. Modifications of ultradian and circadian rhythms of fetal heart rate after fetal-maternal adrenal gland suppression: A double blind study. Prenat Diagn 1986, 6(6):409-417.
173. Onishi S., Miyazawa G., Nishimura Y., Sugiyama S., Yamakawa T., Inagaki H., et al. Postnatal development of circadian rhythm in serum cortisol levels in children. Pediatrics 1983, 72(3):399-404.
174. Keys A. The residues of malnutrition and starvation. Science 1950, 112(2909):371-373.
175. Jeong K.H., Jacobson L., Widmaier E.P., Majzoub J.A. Normal suppression of the reproductive axis following stress in corticotropin-releasing hormone-deficient mice. Endocrinology 1999, 140(4):1702-1708.
176. Rivier C. Inhibitory effect of neurogenic and immune stressors on testosterone secretion in rats. Neuroimmunomodulation 2002, 10(1):17-29.
177. McEwen B.S. The neurobiology of stress: From serendipity to clinical relevance. Brain Res 2000, 886(1-2):172-189.
178. Karalis K., Sano H., Redwine J., Listwak S., Wilder R.L., Chrousos G.P. Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo. Science 1991 Oct 18, 254(5030):421-423.
179. Muglia L.J., Jenkins N.A., Gilbert D.J., Copeland N.G., Majzoub J.A. Expression of the mouse corticotropin-releasing hormone gene in vivo and targeted inactivation in embryonic stem cells. J Clin Invest 1994, 93(5):2066-2072.
180. Reichlin S. Neuroendocrinology, Williams Textbook of Endocrinology 1998, W.B. Saunders Company, Philadelphia, pp. 165-248.
181. Shepard T.H., Landing B.H., Mason D.G. Familial Addison's disease. Case reports of two sisters with corticoid deficiency unassociated with hypoaldosteronism. Am J Dis Child 1959, 97:154-162.
182. Weber A., Clark A.J., Perry L.A., Honour J.W., Savage M.O. Diminished adrenal androgen secretion in familial glucocorticoid deficiency implicates a significant role for ACTH in the induction of adrenarche. Clin Endocrinol (Oxf) 1997, 46:431-437.
183. Chida D., Nakagawa S., Nagai S., Sagara H., Katsumata H., Imaki T., et al. Melanocortin 2 receptor is required for adrenal gland development, steroidogenesis, and neonatal gluconeogenesis. Proc Nat Acad Sci USA 2007, 104(46):18205-18210.
184. Clark A.J., McLoughlin L., Grossman A. Familial glucocorticoid deficiency associated with point mutation in the adrenocorticotropin receptor. Lancet 1993, 341:461-462.
185. Stratakis C.A. Cushing syndrome caused by adrenocortical tumors and hyperplasias (corticotropin-independent Cushing syndrome). Endocr Dev 2008, 13:117-132.
186. Bourdeau I., Lampron A., Costa M.H., Tadjine M., Lacroix A. Adrenocorticotropic hormone-independent Cushing's syndrome. Curr Opin Endocrinol Diabetes Obes 2007, 14(3):219-225.
187. Kirschner L.S., Carney J.A., Pack S.D., Taymans S.E., Giatzakis C., Cho Y.S., et al. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet 2000, 26(1):89-92.
188. Scheithauer B.W. Surgical pathology of the pituitary: The adenomas. Part II. Pathol Annu 1984, 19(Pt 2):269-329.
189. Apletalina E.V., Muller L., Lindberg I. Mutations in the catalytic domain of prohormone convertase 2 result in decreased binding to 7B2 and loss of inhibition with 7B2 C-terminal peptide. J Biol Chem 2000, 275:14667-14677.
190. Neilson K., de Chadarevian J.P. Ectopic anterior pituitary corticotropic tumour in a six-year-old boy. Histological, ultrastructural and immunocytochemical study. Virchows Arch A Pathol Anat Histopathol 1987, 411(3):267-273.
191. Arioglu E., Doppman J., Gomes M., Kleiner D., Mauro D., Barlow C., et al. Cushing's syndrome caused by corticotropin secretion by pulmonary tumorlets. N Engl J Med 1998, 339(13):883-886.
192. Mendonca B.B., Arnhold I.J., Nicolau W., Avancini V.A., Boise W. Cushing's syndrome due to ectopic ACTH secretion by bilateral pheochromocytomas in multiple endocrine neoplasia type 2A. N Engl J Med 1988, 319(24):1610-1611.
193. Melmed S., Yamashita S., Kovacs K., Ong J., Rosenblatt S., Braunstein G. Cushing's syndrome due to ectopic proopiomelanocortin gene expression by islet cell carcinoma of the pancreas. Cancer 1987, 59(4):772-778.